Schmidl, Christian 
; Vladimer, Gregory I. ; Rendeiro, André F. ; Schnabl, Susanne ; Krausgruber, Thomas ; Taubert, Christina ; Krall, Nikolaus ; Pemovska, Tea ; Araghi, Mohammad ; Snijder, Berend ; Hubmann, Rainer ; Ringler, Anna ; Runggatscher, Kathrin ; Demirtas, Dita ; de la Fuente, Oscar Lopez ; Hilgarth, Martin ; Skrabs, Cathrin ; Porpaczy, Edit ; Gruber, Michaela ; Hoermann, Gregor ; Kubicek, Stefan ; Staber, Philipp B. ; Shehata, Medhat ; Superti-Furga, Giulio ; Jäger, Ulrich ; Bock, Christoph
; Vladimer, Gregory I. ; Rendeiro, André F. ; Schnabl, Susanne ; Krausgruber, Thomas ; Taubert, Christina ; Krall, Nikolaus ; Pemovska, Tea ; Araghi, Mohammad ; Snijder, Berend ; Hubmann, Rainer ; Ringler, Anna ; Runggatscher, Kathrin ; Demirtas, Dita ; de la Fuente, Oscar Lopez ; Hilgarth, Martin ; Skrabs, Cathrin ; Porpaczy, Edit ; Gruber, Michaela ; Hoermann, Gregor ; Kubicek, Stefan ; Staber, Philipp B. ; Shehata, Medhat ; Superti-Furga, Giulio ; Jäger, Ulrich ; Bock, Christoph 
Zusammenfassung
The Bruton tyrosine kinase (BTK) inhibitor ibrutinib has substantially improved therapeutic options for chronic lymphocytic leukemia (CLL). Although ibrutinib is not curative, it has a profound effect on CLL cells and may create new pharmacologically exploitable vulnerabilities. To identify such vulnerabilities, we developed a systematic approach that combines epigenome profiling (charting the ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Altmetric